methyl-4-(piperidin-4-ylmethyl)benzoate | 439811-14-0

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 英文名称: methyl-4-(piperidin-4-ylmethyl)benzoate
• 英文别名: 4-(4-methoxycarbonyl-benzyl)-piperidine；4-Piperidin-4-ylmethyl-benzoic acid methyl ester；methyl 4-(piperidin-4-ylmethyl)benzoate
• CAS: 439811-14-0
• 化学式: C₁₄H₁₉NO₂
• 分子量: 233.31
• InChiKey: RMWYXTUXQXGDBW-UHFFFAOYSA-N

物化性质

• 沸点：
  362.1±30.0 °C(Predicted)
• 密度：
  1.066±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.9
• 重原子数：
  17
• 可旋转键数：
  4
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  38.3
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  methyl-4-(piperidin-4-ylmethyl)benzoate 在 sodium hydroxide 、 potassium carbonate 、 potassium iodide 作用下， 以 甲醇 、 N,N-二甲基甲酰胺 、 乙腈 为溶剂， 反应 3.0h， 生成 4-({1-[3-((3,4-Dichlorophenyl){[1-(methylsulfonyl)piperidin-4-yl]carbonyl}amino)propyl]piperidin-4-yl}methyl)benzoic acid
  参考文献：
  名称：

  Discovery of a Piperidine-4-carboxamide CCR5 Antagonist (TAK-220) with Highly Potent Anti-HIV-1 Activity

  摘要：

  We incorporated various polar groups into previously described piperidine-4-carboxamide CCR5 antagonists to improve their metabolic stability in human hepatic microsomes. Introducing a carbamoyl group into the phenyl ring of the 4-benzylpiperidine moiety afforded the less lipophilic compound 5f, which possessed both high metabolic stability and good inhibitory activity of HIV-1 envelope-mediated membrane fusion (IC50 = 5.8 nM). Further optimization to increase potency led to the discovery of 1-acetyl-N-{3-[4-(4-carbamoylbenzyl) piperidin-1-yl]propyl}-N-(3-chloro-4-methylphenyl)piperidine-4-carboxamide (5m, TAK-220), which showed high CCR5 binding affinity (IC50 = 3.5 nM) and potent inhibition of membrane fusion (IC50 = 0.42 nM), as well as good metabolic stability. Compound 5m strongly inhibited the replication of CCR5-using HIV-1 clinical isolates in human peripheral blood mononuclear cells (mean EC50 = 1.1 nM, EC90 = 13 nM) and exhibited a good pharmacokinetic profile in monkeys (BA = 29%). This compound has been chosen as a clinical candidate for further development.

  DOI：

  10.1021/jm051034q
• 作为产物：
  描述：

  4-(4-甲氧基羰基亚苄基)哌啶-1-羧酸叔丁酯 在 盐酸 、 palladium on activated charcoal 、 氢气 作用下， 以 甲醇 、 乙酸乙酯 为溶剂， 生成 methyl-4-(piperidin-4-ylmethyl)benzoate
  参考文献：
  名称：

  针对 CCR5 辅助受体和 gp41 N 端七肽重复区域的双功能人类免疫缺陷病毒 1 型进入抑制剂设计的“双鸟一石”方法

  摘要：

  先前的研究报告了 1 型人类免疫缺陷病毒 (HIV-1) 进入的逐步性质以及辅助受体 CCR5 和 gp41 N 端七肽重复 (NHR) 区域在该事件中的关键作用。考虑到这一点，我们在此报告了一种具有双功能进入抑制剂的双靶向药物化合物，由基于哌啶-4-甲酰胺的 CCR5 拮抗剂 TAK-220 和 gp41 NHR 靶向融合抑制肽 C34 组成。所得嵌合体是通过将两个药效团与聚乙二醇间隔物连接起来而构建的。一种嵌合体 CP12TAK 表现出异常有效的抗病毒活性，分别是其母体抑制剂 C34 和 TAK-220 的 40 倍和 306 倍。除了 R5-tropic 病毒，CP12TAK 还强烈抑制 X4-tropic HIV-1 毒株的感染。这些数据为 CP12TAK 作为一种新型抗 HIV-1 药物的进一步开发提供了希望。结果表明，该策略可以扩展到针对其他包膜病毒感染的疗法的设计。

  DOI：

  10.1021/acs.jmedchem.1c00781

文献信息

• [EN] BENZODIOXANES FOR INHIBITING LEUKOTRIENE PRODUCTION<br/>[FR] BENZODIOXANNES POUR INHIBER LA PRODUCTION DE LEUCOTRIÈNES
  申请人：BOEHRINGER INGELHEIM INT

  公开号：WO2013134226A1

  公开（公告）日：2013-09-12

  The present invention relates to compounds of formula (I) wherein R1 to R3, A, X and n are as defined herein. The compounds of formula (I) are useful as inhibitors of leukotriene A4 hydrolase (LTA4H) and treating LTA4H related disorder. The present invention also relates to pharmaceutical compositions comprising the compounds of formula (I), methods of using these compounds in the treatment of various diseases and disorders, and processes for preparing these compounds.

  本发明涉及式（I）的化合物，其中R1至R3，A，X和n如本文所定义。式（I）的化合物可用作白三烯A4水解酶（LTA4H）的抑制剂，并用于治疗与LTA4H相关的疾病。本发明还涉及包含式（I）化合物的药物组合物，使用这些化合物治疗各种疾病和疾病的方法，以及制备这些化合物的方法。
• BENZODIOXANE INHIBITORS OF LEUKOTRIENE PRODUCTION FOR COMBINATION THERAPY
  申请人：BYLOCK Lars Anders

  公开号：US20130236468A1

  公开（公告）日：2013-09-12

  The present invention relates to a combination comprising compounds of formula (I): wherein R 1 to R 3 , A, X and n are as defined herein, and an additional active agent. The present invention also relates to pharmaceutical compositions comprising these combinations, and methods of using these combinations to treat various diseases and disorders.

  本发明涉及一种组合物，包括式（I）的化合物： 其中R1至R3，A，X和n如本文所定义，并且另外包括一种活性剂。本发明还涉及包括这些组合物的药物组合物，以及使用这些组合物治疗各种疾病和疾病的方法。
• [EN] BENZODIOXANE INHIBITORS OF LEUKOTRIENE PRODUCTION<br/>[FR] INHIBITEURS BENZODIOXANES DE PRODUCTION DE LEUCOTRIÈNES
  申请人：BOEHRINGER INGELHEIM INT

  公开号：WO2012125598A1

  公开（公告）日：2012-09-20

  The present invention relates to compounds of formula (I): wherein R1 to R3, A, X and n are as defined herein. The compounds of formula (I) are useful as inhibitors of leukotriene A4 hydrolase (LTA4H) and treating LTA4H related disorder. The present invention also relates to pharmaceutical compositions comprising the compounds of formula (I), methods of using these compounds in the treatment of various diseases and disorders, and processes for preparing these compounds.

  本发明涉及式(I)的化合物：其中R1至R3、A、X和n如本文所定义。式(I)的化合物可用作白三烯A4水解酶(LTA4H)的抑制剂，并用于治疗与LTA4H相关的疾病。本发明还涉及包含式(I)化合物的药物组合物，使用这些化合物治疗各种疾病和疾病的方法，以及制备这些化合物的方法。
• [EN] NEW BENZOYL UREA DERIVATIVES<br/>[FR] NOUVEAUX DERIVES D'UREE BENZOYLE
  申请人：RICHTER GEDEON VEGYESZET

  公开号：WO2006010966A1

  公开（公告）日：2006-02-02

  The new benzoyl urea derivatives of formula (I) wherein the meaning of X and Y independently are hydrogen atom, hydroxy, benzyloxy, amino, nitro, C1-C4 alkylsulfonamido optionally substituted with a halogen atom or halogen atoms, C1-C4 alkanoylamido optionally substituted with a halogen atom or halogen atoms, C1-C4 alkoxy, aroyl-carbamoyl optionally substituted with halogen atom or C1-C4 alkyl or C1-C4 alkoxycarbonyl group, or the neighboring X and Y groups optionally form together with one or more identical or different additional hetero atom and -CH= and/or -CH2- groups an optionally substituted 4-7 membered homo- or heterocyclic ring, preferably morpholine, pyrrole, pyrrolidine, oxo- or thioxo-pyrrolidine, pyrazole, pyrazolidine, imidazole, imidazolidine, oxo- or thioxo-imidazole or imidazolidine, 1,4-oxazine, oxazole, oxazolidine, triazole, oxo- or thioxo-oxazolidine, or 3-oxo-l,4-oxazine ring, V and Z independently are hydrogen or halogen atom, cyano, C1-C4 alkyl, C1-C4 alkoxy, trifluoromethyl, hydroxy or optionally esterized carboxyl group, W is oxygen atom, as well as C1-C4 alkylene, C2-C4 alkenylene, aminocarbonyl, -NH-, -N(alkyl)-, -CH2O-, -CH2S-, -CH(OH)-, -OCH2- group, wherein the meaning of alkyl is a C1-C4 alkyl group -, when the dotted bonds ( --- ) represent simple C-C bonds then U is hydroxy group or hydrogen atom or when W is C1-C4 alkylene or C2-C4 alkenylene group, then one of the dotted bonds ( --- ) can represent a further double C-C bond and in this case U means an electron pair, which participate in the double bond and optical antipodes, racemates and the salts thereof are highly effective and selective antagonists of NMDA receptor, and moreover most of the compounds are selective antagonist of NR2B subtype of NMDA receptor. Furthermore objects of the present invention are the pharmaceutical compositions containing new benzoyl urea derivatives of formula (I) or optical antipodes or racemates or the salts thereof as active ingredients and processes for producing these compounds and pharmaceutical compositions.

  公式（I）的新苯甲酰脲衍生物，其中X和Y的含义独立地是氢原子、羟基、苄氧基、氨基、硝基、C1-C4烷基磺酰胺（可选择地与卤原子或卤原子取代）、C1-C4烷酰胺（可选择地与卤原子或卤原子取代）、C1-C4烷氧基、芳酰基-氨基（可选择地与卤原子或C1-C4烷基或C1-C4烷氧羰基团取代）或相邻的X和Y基团可选择地与一个或多个相同或不同的额外杂原子和-CH=和/或-CH2-基团一起形成一个可选择地取代的4-7成员同源或异源环，优选为吗啡啉、吡咯、吡咯烷、氧代或硫代吡咯烷、吡唑、吡唑烷、咪唑、咪唑烷、氧代或硫代咪唑或咪唑烷、1,4-氧杂噁啉、氧唑、氧杂噁啉、三唑、氧代或硫代氧杂噁啉或3-氧代-1,4-氧杂噁啉环，V和Z独立地是氢或卤原子、氰基、C1-C4烷基、C1-C4烷氧基、三氟甲基、羟基或可选择酯化的羧基，W是氧原子，以及C1-C4烷基、C2-C4烯基、氨基羰基、-NH-、-N(烷基)-、-CH2O-、-CH2S-、-CH(OH)-、-OCH2-基团，其中烷基的含义是C1-C4烷基群-，当虚线键（---）代表简单的C-C键时，U是羟基或氢原子，或当W是C1-C4烷基或C2-C4烯基群时，那么虚线键（---）中的一个可以代表进一步的双键C-C键，在这种情况下，U表示参与双键和光学异构体、消旋体及其盐的电子对，这些化合物是NMDA受体的高效和选择性拮抗剂，而且大多数化合物是NMDA受体NR2B亚型的选择性拮抗剂。此外，本发明的目的是包含公式（I）的新苯甲酰脲衍生物、光学异构体或消旋体或其盐为活性成分的药物组合物，以及生产这些化合物和药物组合物的方法。
• BENZODIOXANE INHIBITORS OF LEUKOTRIENE PRODUCTION
  申请人：Abeywardane Asitha

  公开号：US20130196973A1

  公开（公告）日：2013-08-01

  The present invention relates to compounds of formula (I): wherein R 1 to R 3 , A, X and n are as defined herein. The compounds of formula (I) are useful as inhibitors of leukotriene A 4 hydrolase (LTA4H) and treating LTA4H related disorder. The present invention also relates to pharmaceutical compositions comprising the compounds of formula (I), methods of using these compounds in the treatment of various diseases and disorders, and processes for preparing these compounds.

  本发明涉及式(I)化合物，其中R1至R3，A，X和n的定义如本文所述。式(I)化合物可用作白三烯A4水解酶（LTA4H）的抑制剂，并用于治疗LTA4H相关疾病。本发明还涉及包含式(I)化合物的制药组合物，使用这些化合物治疗各种疾病和疾患的方法，以及制备这些化合物的方法。